Leonardo Di Cesare
Research Subjects
Leonardo Di Cesare has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alimamy Serry-Bangura
Vaccines Global Safety, GSK, Siena, Italy
1 shared publication Ashwani Kumar Arora
Vaccines Institute for Global Health (Global Health Vaccines R&D), GSK, Siena, Italy
1 shared publication- Audino Podda
GSK Vaccines Institute for Global Health, Siena, Italy
1 shared publication - Bassey Edem
Vaccines Institute for Global Health (Global Health Vaccines R&D), GSK, Siena, Italy
1 shared publication - Danilo Gomes Moriel
GSK Vaccines Institute for Global Health (GVGH), Siena, Italy
1 shared publication - Iris De Ryck
GSK Vaccines Clinical Safety and Pharmacovigilance (VCSP) Department, Siena, Italy
1 shared publication
Latest Publications
- Open Access
- 18 March 2024
- Published by Springer Nature in Drugs in R&D
- Vol. 24 (1) , 1-12
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes
Superficial infections with Streptococcus pyogenes (Strep A), pharyngitis and impetigo can induce acute rheumatic fever, an autoimmune sequela manifesting mostly with arthritis and rheumatic carditis. Valvular heart damage can persist or advance following repeated episodes of acute rheumatic fever, causing rheumatic heart disease. Acute rheumatic fever and rheumatic heart disease disproportionately affect children and young adults in developing countries and disadvantaged communities in developed countries. People living with rheumatic heart disease are at risk of experiencing potentially fatal complications such as heart failure, bacterial endocarditis or stroke. Transthoracic echocardiography plays a central role in diagnosing both rheumatic carditis and rheumatic heart disease. Despite the obvious medical need, no licensed Strep A vaccines are currently available, as their clinical development process faces several challenges, including concerns for cardiac safety. However, the development of Strep A vaccines has been recently relaunched by many vaccine developers. In this context, a reliable and consistent safety evaluation of Strep A vaccine candidates, including the use of transthoracic echocardiography for detecting cardiac adverse events, could greatly contribute to developing a safe and efficacious product in the near future. Here, we propose a framework for the consistent use of transthoracic echocardiography to proactively detect cardiac safety events in clinical trials of Strep A vaccine candidates.
- 18 March 2024
- Published by Springer Nature in Drugs in R&D
- Vol. 24 (1) , 1-12
Open AccessApplication of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes
Superficial infections with Streptococcus pyogenes (Strep A), pharyngitis and impetigo can induce acute rheumatic fever, an autoimmune sequela manifesting mostly with arthritis and rheumatic carditis. Valvular heart damage can persist or advance following repeated episodes of acute rheumatic fever, causing rheumatic heart disease. Acute rheumatic fever and rheumatic heart disease disproportionately affect children and young adults in developing countries and disadvantaged communities in developed countries. People living with rheumatic heart disease are at risk of experiencing potentially fatal complications such as heart failure, bacterial endocarditis or stroke. Transthoracic echocardiography plays a central role in diagnosing both rheumatic carditis and rheumatic heart disease. Despite the obvious medical need, no licensed Strep A vaccines are currently available, as their clinical development process faces several challenges, including concerns for cardiac safety. However, the development of Strep A vaccines has been recently relaunched by many vaccine developers. In this context, a reliable and consistent safety evaluation of Strep A vaccine candidates, including the use of transthoracic echocardiography for detecting cardiac adverse events, could greatly contribute to developing a safe and efficacious product in the near future. Here, we propose a framework for the consistent use of transthoracic echocardiography to proactively detect cardiac safety events in clinical trials of Strep A vaccine candidates.